HC Wainwright reissued their buy rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note published on Monday morning. The firm currently has a $158.00 target price on the biopharmaceutical company’s stock.
Several other equities analysts also recently issued reports on TSRO. Robert W. Baird reissued a neutral rating and issued a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Jefferies Group LLC set a $124.00 target price on TESARO and gave the company a hold rating in a research report on Thursday, August 17th. Morgan Stanley reissued an overweight rating and issued a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. Leerink Swann raised TESARO from a market perform rating to an outperform rating in a research report on Wednesday, November 15th. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the company a buy rating in a research report on Friday, August 18th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. TESARO has a consensus rating of Buy and an average price target of $161.72.
Shares of TESARO (NASDAQ TSRO) opened at $83.54 on Monday. TESARO has a twelve month low of $83.35 and a twelve month high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. During the same quarter in the prior year, the business posted ($1.72) EPS. The business’s revenue for the quarter was up 740.3% compared to the same quarter last year. analysts predict that TESARO will post -8.16 earnings per share for the current fiscal year.
WARNING: “TESARO, Inc. (TSRO) Given “Buy” Rating at HC Wainwright” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/11/21/tesaro-inc-tsro-given-buy-rating-at-hc-wainwright.html.
In other news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the sale, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,692 shares of company stock worth $4,628,976. Corporate insiders own 34.60% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Exane Derivatives purchased a new position in TESARO in the 3rd quarter valued at about $106,000. Botty Investors LLC purchased a new position in TESARO in the 2nd quarter valued at about $140,000. Nordea Investment Management AB purchased a new position in TESARO in the 2nd quarter valued at about $167,000. Oppenheimer Asset Management Inc. lifted its stake in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares in the last quarter. Finally, Toronto Dominion Bank lifted its stake in TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares in the last quarter.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.